Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might have in store.
Source link
- November pending home sales were unchanged, despite a sharp drop in mortgage rates
- Why the $7,500 electric vehicle tax credit may be easier — and harder — to get in 2024
